<DOC>
	<DOCNO>NCT02921815</DOCNO>
	<brief_summary>To analyze occurrence transformation myelodysplastic syndrome ( MDS ) acute myeloid leukemia ( hereinafter refer transformation MDS AML ) patient myelodysplastic syndrome deletion 5q cytogenetic abnormality ( hereinafter refer del ( 5q ) MDS ) receive Revlimid® 5 mg Capsules ( hereinafter refer Revlimid ) continue longer continue Revlimid treatment . 1 . Planned registration period This period start date initial marketing Revlimid end day appropriateness enrollment assess del ( 5qMDS ) patient all-case surveillance . 2 . Planned surveillance period This period start date initial marketing Revlimid end 3 year last enrol patient begin receive Revlimid .</brief_summary>
	<brief_title>A Study Analyze Occurrence Transformation From Myelodysplastic Syndrome Acute Myeloid Leukemia Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules Who Are Continuing Longer Continuing Revlimid Treatment</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>All del ( 5q ) MDS patient allcase surveillance transformation acute myeloid leukemia ( hereinafter refer AML ) document end observation period allcase surveillance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Revlimid</keyword>
</DOC>